Addex Therapeutics Ltd (ADXN) - Total Liabilities
Based on the latest financial reports, Addex Therapeutics Ltd (ADXN) has total liabilities worth CHF1.47 Million CHF (≈ $1.86 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Addex Therapeutics Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Addex Therapeutics Ltd - Total Liabilities Trend (2006–2025)
This chart illustrates how Addex Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Addex Therapeutics Ltd total assets.
Addex Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Addex Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Intelligent Group Limited Ordinary Shares
NASDAQ:INTJ
|
USA | $5.11 Million |
|
Cemtrex Inc
NASDAQ:CETX
|
USA | $38.01 Million |
|
TwentyFour Select Monthly Income Fund Ltd
LSE:SMIF
|
UK | GBX9.95 Million |
|
Groupe Airwell Société anonyme
PA:ALAIR
|
France | €35.54 Million |
|
Aldrich Resources Bhd
KLSE:0079
|
Malaysia | RM22.34 Million |
|
G Capital Public Company Limited
BK:GCAP
|
Thailand | ฿497.60 Million |
|
Keyang Electric Machinery Co Ltd
KO:012205
|
Korea | ₩191.85 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down Addex Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ADXN net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Addex Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Addex Therapeutics Ltd (2006–2025)
The table below shows the annual total liabilities of Addex Therapeutics Ltd from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CHF1.60 Million ≈ $2.02 Million |
+59.59% |
| 2024-12-31 | CHF1.00 Million ≈ $1.27 Million |
-71.37% |
| 2023-12-31 | CHF3.50 Million ≈ $4.42 Million |
+3.78% |
| 2022-12-31 | CHF3.37 Million ≈ $4.26 Million |
-39.95% |
| 2021-12-31 | CHF5.61 Million ≈ $7.09 Million |
+0.69% |
| 2020-12-31 | CHF5.57 Million ≈ $7.04 Million |
-25.76% |
| 2019-12-31 | CHF7.50 Million ≈ $9.49 Million |
+152.42% |
| 2018-12-31 | CHF2.97 Million ≈ $3.76 Million |
+72.79% |
| 2017-12-31 | CHF1.72 Million ≈ $2.18 Million |
+17.50% |
| 2016-12-31 | CHF1.46 Million ≈ $1.85 Million |
+19.49% |
| 2015-12-31 | CHF1.23 Million ≈ $1.55 Million |
-25.89% |
| 2014-12-31 | CHF1.65 Million ≈ $2.09 Million |
-42.06% |
| 2013-12-31 | CHF2.85 Million ≈ $3.61 Million |
-47.59% |
| 2012-12-31 | CHF5.44 Million ≈ $6.88 Million |
-44.33% |
| 2011-12-31 | CHF9.78 Million ≈ $12.36 Million |
-0.91% |
| 2010-12-31 | CHF9.87 Million ≈ $12.48 Million |
-10.05% |
| 2009-12-31 | CHF10.97 Million ≈ $13.87 Million |
-17.73% |
| 2008-12-31 | CHF13.34 Million ≈ $16.86 Million |
+43.92% |
| 2007-12-31 | CHF9.27 Million ≈ $11.72 Million |
+127.45% |
| 2006-12-31 | CHF4.07 Million ≈ $5.15 Million |
-- |
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-in… Read more